Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment firm Trium Capital LLP has disclosed an 11.01% stake in Mural Oncology PLC, according to a regulatory filing published Wednesday.
The disclosure, made under Irish takeover rules, reveals Trium holds interests in 1,901,782 shares of the oncology company. This position includes 1,847,526 relevant securities owned or controlled, representing 10.70% of the company, and 54,256 cash-settled derivatives accounting for an additional 0.31%.
The filing also shows Trium purchased 26,289 shares at a price of $2.0696 per unit on September 30, 2025.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests representing 1% or more in a company to disclose their positions.
Trium Capital indicated in the filing that it has no indemnity or option arrangements, agreements, or understandings relating to Mural Oncology’s securities.
The disclosure comes as an opening position statement, suggesting potential takeover activity involving Mural Oncology, though no specific offer details were mentioned in the filing.
The information was submitted to the Regulatory Information Service as required by Irish takeover regulations, based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.